$1.600
-0.029 (-1.84%)Al cierre
Noticias de HIND
Eventos de HIND
Vyome Receives USPTO Allowance for VT-1908 Patent
Vyome announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for U.S. Patent Application No. 17/787,303, titled "Formulations and Method for Treatment of Inflammatory Diseases." The USPTO has allowed the multiple claims filed under the above application number covering formulations and methods of use underlying Vyome's VT-1908 program.
Vyome Appoints Jerry Leonard as Chief Financial Officer
Vyome (HIND) announced the appointment of senior financial executive Jerry Leonard, CPA, MBA, as Chief Financial Officer. Leonard has assumed the role from September 1st, 2026 and will oversee the Company's financial operations, financial reporting, accounting, internal controls, and related corporate governance responsibilities. Leonard succeeds Robert Dickey, IV, who served as Interim Chief Financial Officer since August 2025. Leonard served as Senior Vice President, Chief Financial Officer, and Secretary of VSee Health (VSEE) following its 2024 business combination
Vyome Holdings Appoints Jerry Leonard as CFO
In a regulatory filing, the company stated, "On August 27, 2026, the board of directors of Vyome Holdings appointed Jerry Leonard as the company's Chief Financial Officer. In connection with Leonard's appointment, the Board, upon the recommendation of the compensation committee of the Board, approved a Consulting Agreement with ClearbridgeCFO, LLC, a Georgia limited liability company, and Leonard, pursuant to which ClearBridge will assign Leonard to provide services as the company's Chief Financial Officer, effective as of September 1, 2026. In connection with his appointment, as of the Effective Date, Leonard will serve as the company's principal financial officer and principal accounting officer. On August 25, 2026, Robert Dickey notified the company's board of directors of his intention to voluntary resignation from his position as Interim Chief Financial Officer effective August 31, 2026. Dickey's resignation was not the result of any disagreement with the company on any matter relating to the company's operations, policies, or practices. In connection with Dickey's resignation, the company's consulting agreement with Foresite Advisors, LLC, dated August 26, 2024, will be deemed terminated as of August 31, 2026."
Vyome Holdings Cash and Cash Equivalents Reach $7.9 Million
Cash and cash equivalents were approximately $7.9 million as of June 30, 2026, compared with approximately $5.0 million as of December 31, 2025. Krishna Gupta, Chairman, Vyome Holdings, said, "Vyome continues to execute with focus and discipline across its development programs while maintaining a methodical and conservative approach to capital allocation. During the quarter, we advanced our lead VT-1953 program, broadened our pipeline through the Impetis agreement and continued to strengthen our intellectual property portfolio. With a strong balance sheet and disciplined capital structure, we believe Vyome is well positioned to pursue its development priorities and create long-term shareholder value."
Vyome Holdings Signs Exclusive Agreement with Impetis Biosciences
Vyome Holdings announced the signing of an agreement with Impetis Biosciences, a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. "We are building Vyome with focus and discipline in one of the most attractive segments in biotech, the immuno-inflammatory market, expected to exceed $430 billion by 2034, with the JAK inhibitor segment alone representing a significant ~$57 billion opportunity," said Venkat Nelabhotla, CEO of Vyome. "This transaction highlights the strength of the US-India innovation corridor in sourcing high-quality assets efficiently. The transaction is structured to be very capital-efficient, with consideration tied to commercialization. Any future development will be driven through non-dilutive pathways, allowing us to remain fully focused on executing our core strategy around VT-1953."
Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.